Novartis has expressed disappointment over a recommendation by the European Medicines Agency to revoke the EU conditional marketing authorization (CMA) for its sickle cell disease drug, Adakveo (crizanlizumab), because the product had failed to meet one of the specific obligations of the conditional approval.
EMA Recommends Revoking EU Approval For Novartis’s Sickle Cell Disease Drug
The results of a Phase III study did not confirm the benefits previously seen with Adakveo, the European Medicines Agency said.
